SAB’s therapeutic candidate, SAB-185, is a new immunotherapy generated from the company’s proprietary technology, the DiversitAb™ platform, to produce fully human polyclonal antibodies that target ...
SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high-potency, fully human polyclonal antibodies ...
FDA greenlights advancement of SAB-176 Phase 2b trial and manufacturing approach to address influenza strain change SAB-176 is the first fully-human broadly neutralizing immunoglobulin antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results